Smart AUC/MIC Pharmacokinetic Calculator
Comprehensive Universal Antibiotic Reference Model
| Antibiotic Class | Agent Name | Standard Adult Dosing | Average 24h AUC Baseline | Target Ratio Threshold |
|---|---|---|---|---|
| Oxazolidinones | Linezolid (Zyvox) Tedizolid (Sivextro) | 600 mg PO/IV every 12h 200 mg PO/IV every 24h | 160 mg•h/L 30 mg•h/L | ≥ 80 – 100 (VRE/MRSA) ≥ 3 |
| Lipopeptides | Daptomycin (Cubicin) | 6 mg/kg IV every 24h 8 mg/kg IV every 24h 10-12 mg/kg IV every 24h | 450 mg•h/L 590 mg•h/L 780 mg•h/L | ≥ 75 – 105 (Bactericidal) |
| Fluoroquinolones | Levofloxacin (Levaquin) | 500 mg PO/IV every 24h 750 mg PO/IV every 24h | 48 mg•h/L 125 mg•h/L | ≥ 30 – 50 (Gram-Positive) ≥ 100 – 125 (Gram-Negative) |
| Ciprofloxacin (Cipro) | 500 mg PO every 12h 400 mg IV every 12h | 30 mg•h/L 60 mg•h/L | ||
| Moxifloxacin (Avelox) | 400 mg PO/IV every 24h | 45 mg•h/L | ||
| Glycopeptides | Vancomycin (Vancocin) Telavancin (Vibativ) | Weight/Renal Stratified 10 mg/kg IV every 24h | 400 – 600 mg•h/L 90 mg•h/L | 400 to 600 (MRSA Guide) ≥ 215 |
| Aminoglycosides | Gentamicin / Tobramycin | 5 mg/kg IV every 24h (Consolidated) 1.7 mg/kg IV every 8h (Traditional) | 90 mg•h/L 65 mg•h/L | ≥ 70 – 100 (Gram-Negative Rods) |
| Amikacin (Amikin) | 15 mg/kg IV every 24h | 240 mg•h/L | ||
| Tetracyclines / Glycyl | Tigecycline (Tygacil) | 100mg load, then 50mg every 12h | 25 mg•h/L | ≥ 12.5 – 25 |
| Doxycycline (Vibramycin) | 100 mg PO/IV every 12h | 95 mg•h/L | ≥ 25 | |
| Macrolides | Azithromycin (Zithromax) | 500 mg PO day 1, then 255 mg daily | 12 mg•h/L | ≥ 25 (Atypical strains) |
Clinical Importance of the AUC to MIC Exposure Ratio
In antimicrobial pharmacodynamics, the ratio of the 24-hour Area Under the Curve (AUC) to the pathogen’s Minimum Inhibitory Concentration (MIC) is the primary predictor of clinical success for a wide range of antibiotic classes. Unlike beta-lactams, which require prolonged time intervals above a specific concentration line, drugs evaluated by AUC-to-MIC ratios are driven by total cumulative drug exposure relative to the organism’s defenses.
Mathematical Relationships: Deriving AUC from Clearance Metrics
When direct serum sampling profiles are unavailable to calculate a precise geometric area, clinical pharmacokinetics allows clinicians to derive the 24-hour total concentration area through baseline clearance variables.
Because the total area under a plasma concentration-time curve at steady state is directly proportional to the total daily dose divided by body clearance, computing this ratio allows a bedside clinician to predict clinical outcomes using regular dosing schedules and standard kidney clearance estimates.
Target Variability Across Unique Antimicrobial Classes
The absolute numeric target for an optimized AUC-to-MIC calculation changes significantly depending on the chemical properties of the drug and the structural differences of the target bacterial cell wall:
- Fluoroquinolones (e.g., Levofloxacin, Ciprofloxacin): Treating severe Gram-negative infections like Pseudomonas aeruginosa requires strict target thresholds between 100 and 125 to achieve bactericidal clearance and prevent resistance selection. For Gram-positive targets like Streptococcus pneumoniae, lower ratios between 30 and 50 are routinely sufficient.
- Oxazolidinones and Lipopeptides (e.g., Linezolid, Daptomycin): These modern anti-MRSA interventions require stable targets tracking between 80 and 100 to maximize tissue penetration and achieve deep microbiological cure profiles.